ImmuPharma plc (LON:IMM – Get Free Report) shares were down 11.7% during trading on Thursday . The stock traded as low as GBX 3.75 ($0.05) and last traded at GBX 3.80 ($0.05). Approximately 14,936,349 shares traded hands during mid-day trading, a decline of 25% from the average daily volume of 19,799,125 shares. The stock had previously closed at GBX 4.31 ($0.05).
ImmuPharma Stock Performance
The company has a market cap of £16.15 million, a P/E ratio of -6.57 and a beta of 1.53. The business has a 50 day moving average price of GBX 2.67 and a two-hundred day moving average price of GBX 2.01.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- What Are Dividend Champions? How to Invest in the Champions
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
